<unk> , sold under the brand name Vabysmo, is a monoclonal antibody used for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).<unk>  is the first bispecific monoclonal antibody, to target both vascular endothelial growth factor (VEGF), and angiopoietin 2 (Ang-2) inhibitor. By targeting these pathways,<unk>  stabilizes blood vessels in the retina. It is given by intravitreal injection (injection into the eye) by an ophthalmologist.<unk>  was developed by Roche.<unk>  completed Phase III trials and was approved for medical use in the United States in January 2022.
Faricimab
Altbib
Odesivimab
Oseltamivir
Maftivimab
Regdanvimab
Atoltivimab
Sotrovimab